However, because, in the PC cohort, previous COVID-19 was more frequent in the control group, one would expect to amplify differences in immune response vs. the anti-CD20 and S1P modulators groups, and no statistical difference in the qualitative humoral and cellular response was observed. This evidence concerns the gene MBTPS1 and COVID-19.